Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis

NCT02948881 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02948881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2005
Completion date
July 31, 2007
Enrollment
100 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis